FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:294-296 January 15, 2009 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ray, W. A. PubMed Citation

Antipsychotic medications are commonly used across the entire age spectrum, both within and outside their labeled (and evidence-based) indications.^1,2 Three atypical antipsychotic medications, olanzapine (Zyprexa, Eli Lilly), risperidone (Risperdal, Janssen), and quetiapine (Seroquel, AstraZeneca) are among the 10 top-selling drugs worldwide, with a combined sales volume of $14.5 billion in 2007.³

A thorough evaluation of risks is particularly important in the case of medications that are used so frequently and in such diverse patients, many of whom (e.g., children and the elderly) are particularly vulnerable. The effect of most antipsychotic medications on the electrophysiology of the heart has long been . . . [Full Text of this Article]

Source Information

From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.

This article has been cited by other articles:

• (2009). Antipsychotic Drugs and Sudden Cardiac Death. JWatch General 2009: 1-1 [Full Text]